Carter J L, Rodriguez M
Department of Neurology, Mayo Clinic Scottsdale, Arizona.
Mayo Clin Proc. 1989 Jun;64(6):664-9. doi: 10.1016/s0025-6196(12)65345-2.
Multiple sclerosis is thought, by many investigators, to be an immunologic disease. Therefore, a rationale exists for treating this disease by immunosuppressive therapy. In exacerbating-remitting multiple sclerosis, corticosteroids and adrenocorticotropic hormone are the most widely used drugs; high doses of intravenously administered methylprednisolone have recently gained favor. Chronic progressive multiple sclerosis has been treated with a number of immunosuppressive regimens, several of which have shown promise to date. Cyclophosphamide and azathioprine have been used most often and are reviewed in this report, as are other agents currently under investigation. No firm guidelines for the treatment of chronic progressive multiple sclerosis can be offered, but an approach to immunosuppressive therapy is suggested in this review.
许多研究人员认为，多发性硬化症是一种免疫性疾病。因此，存在通过免疫抑制疗法治疗该疾病的理论依据。在复发缓解型多发性硬化症中，皮质类固醇和促肾上腺皮质激素是使用最广泛的药物；最近，大剂量静脉注射甲基泼尼松龙受到青睐。慢性进展型多发性硬化症已经采用了多种免疫抑制方案进行治疗，其中一些方案迄今为止已显示出前景。环磷酰胺和硫唑嘌呤使用最为频繁，本报告将对其进行综述，同时也将综述其他目前正在研究的药物。对于慢性进展型多发性硬化症的治疗，目前还无法提供确切的指导方针，但本综述提出了一种免疫抑制疗法的方法。
